title: Recombinant Immunotoxin Therapy of Solid Tumors: Challenges and Strategies.
abstract: Immunotoxins are a group of protein-based therapeutics, basically comprising two functional moieties: one is the antibody or antibody Fv fragment that allows the immunotoxin to bind specifically to target cells; another is the plant or bacterial toxin that kills the cells upon internalization. Immunotoxins have several unique features which are superior to conventional chemotherapeutics, including high specificity, extraordinary potency, and no known drug resistance. Development of immunotoxins evolves with time and technology, but significant progress has been achieved in the past 20 years after introduction of recombinant DNA technique and generation of the first single-chain variable fragment of monoclonal antibodies. Since then, more than 1,000 recombinant immunotoxins have been generated against cancer. However, most success in immunotoxin therapy has been achieved against hematological malignancies, several issues persist to be significant barriers for effective therapy of human solid tumors. Further development of immunotoxins will largely focus on the improvement of penetration capability to solid tumor mass and elimination of immunogenicity occurred when given repeatedly to patients. Promising strategies may include construction of recombinant antibody fragments with higher binding affinity and stability, elimination of immunodominant T- and B-cell epitopes of toxins, modification of immunotoxins with macromolecules like poly(ethylene glycol) and liposomes, and generation of immunotoxins with humanized antibody fragments and human endogenous cytotoxic enzymes. In this paper, we briefly reviewed the evolution of immunotoxin development and then discussed the challenges of immunotoxin therapy for human solid tumors and the potential strategies we may seek to overcome the challenges.
authors.affiliation: Molecular Imaging Laboratory, Department of Radiology, Howard University, Washington DC.
authors.forename: Liang
authors.initials: L
authors.lastname: Shan
authors.affiliation: Angimmune LLC, Rockville, MD.
authors.forename: Yuanyi
authors.initials: Y
authors.lastname: Liu
authors.affiliation: Molecular Imaging Laboratory, Department of Radiology, Howard University, Washington DC.
authors.forename: Paul
authors.initials: P
authors.lastname: Wang
keywords: Recombinant immunotoxin; cancer therapy; challenges; solid tumor; strategies